Timothy Rink, M.A., M.D., Sc.D.

Dr. Rink is director of Kymab Ltd., and previously was chairman of the Wellcome Trust Technology Transfer Strategy Panel, chairman and chief executive officer of Aurora Biosciences, president and chief technical officer of Amylin Pharmaceuticals and vice president for research at SmithKline. In addition, he has served as a director of several biotechnology companies, including Adnexus, Akubio, Alanex, Astex, BioVex, Ciphergen, CoCensys, Gryphon Sciences, Lorantis, NPS Pharmaceuticals, Santhera Pharmaceuticals, Sepracor, Solexa (as chairman, acquired by Illumina), and Stevenage Bioscience Catalyst and served on the scientific advisory board at Serono SA. Dr. Rink has been involved in the development of numerous therapeutics, including Requip®, Protonix®, Symlin®, Byetta®, Sensipar®, and Catena®. He earned a Sc.D., M.A., and M.D. from the University of Cambridge.